Two decades after hitting the Nasdaq as a publicly traded company in 2001, Natus Medical is saying goodbye to all that.
The devicemaker has agreed to be acquired by healthcare-focused private equity firm ArchiMed in a deal that would value it at about $1.2 billion and remove it from public trading, Natus said Monday.
The company’s board of directors has already unanimously approved the agreement and is recommending shareholders follow suit. Pending shareholder approval and other regulatory requirements, the acquisition is expected to be finalized sometime in the third quarter of this year.
Read more: Fierce Biotech
